If you are exploring how to set up an amyloidosis center in Latin America, you might be interested in attending our roundtable meeting.
Our independent medical education program is designed to support multidisciplinary teams in establishing and strengthening specialist amyloidosis services, with region-specific insights to reflect real-world challenges and support implementation.
Early and accurate diagnosis, followed by timely initiation of treatment, is essential for improving outcomes in patients with amyloidosis. However, in Latin America, patients often experience significant diagnostic delays, complicated by the limited number of specialized centers equipped to offer coordinated, multidisciplinary care.
To address these urgent challenges, we are running a virtual roundtable meeting to discuss how to overcome challenges in establishing and operating amyloidosis services in the LATAM region.
We will be joined by three amyloidosis experts who have been instrumental in setting up successful amyloidosis services in their respective countries, Brazil, Argentina, and Mexico.
Co-program directors
Dr Alejandra Gonzalez Duarte (Mexico)
NYU Grossman School of Medicine & NYU Dysautonomia Center, USA
Bio| Time | Session |
|---|---|
| 10 mins | Welcome and Introduction |
| 30 mins | Session 1: Improving diagnosis and referral pathways |
| 30 mins | Session 2: Optimizing amyloidosis treatment in LATAM |
| 30 mins | Session 3: Building effective multidisciplinary collaboration |
| 15 mins | Session 4: Panel discussion and Q&A |
| 5 mins | Closing remarks |
This roundtable discussion will provide a platform for HCPs to engage directly with expert faculty and peers for specialized guidance and discussions around region-specific challenges to setting up a dedicated service, referring patients to existing centers, and improving multidisciplinary collaboration.
The meeting will be conducted in Spanish and Portuguese, with simultaneous translation available.
This meeting is suitable for learners involved in the diagnosis and management of amyloidosis. Please apply for a place at the roundtable if you have an interest in establishing an amyloidosis service in LATAM.
After taking part in this program, you will be able to:
Neurologists, cardiologists, hematologists, gastroenterologists, orthopedic surgeons, nephrologists, geneticists, physiotherapists, psychologists, pathologists, nurses, and other HCPs involved in diagnosis and management of patients with amyloidosis
Márcia Waddington has a Master’s and PhD in Neurology from FM-UFRJ (Federal University of Rio de Janeiro), and a specialist in Clinical Neurophysiology from SBNC/AMB (Brazilian Society of Clinical Neurophysiology/Brazilian Medical Association). She is a permanent faculty member of the postgraduate program in Clinical Medicine at FM-UFRJ, and Principal Investigator at the Amyloidosis Reference Center, CEPARM, University Hospital of UFRJ. Dr Waddington is also Coordinator of the Amyloidosis Care Pathway at the Américas-Vitória-Samaritano Barra RJ Hospital Complex, and Principal Investigator at the Américas Institute for Research and Education.
Disclosures
Márcia Waddington discloses honoraria/consultation fees from Pfizer, AstraZeneca, Alnylam, Ionis, PTC Therapeutics, Eidos, and Johnson&Johnson.
María Adela Aguirre is a physician with a PhD in Internal Medicine and a member of the Amyloidosis Study Group at Hospital Italiano de Buenos Aires. Since 2010, her work has focused on the care of patients with amyloidosis, along with medical education, clinical research, and innovation aimed at improving the understanding and management of this disease.
María Adela Aguirre has no financial disclosures.
Alejandra González-Duarte received her medical degree in Mexico City and has two subspecialties in Internal Medicine and Neurology. After graduating, she underwent two post-doctoral fellowships in Neuroinfectious Diseases and Autonomic Disorders (Mount Sinai and NYU). She returned to Mexico in 2010 where she began diagnosing and treating patients with Hereditary Transthyretin Amyloidosis, following a large cohort of patients.
She was head of the Dysautonomia and Small Nerve Fiber Laboratory in Mexico until 2021 when she relocated to New York to work as Co-Director of the NYU Dysautonomia Center and Carl Seaman Family Clinical Associate Professor of Dysautonomia Treatment and Research in the Department of Neurology at Grossman School of Medicine.
Disclosures
Alejandra González-Duarte has participated in company sponsored speaker bureaux for Pfizer, Intellia, AstraZeneca, and Alnylam.